<DOC>
	<DOC>NCT00088140</DOC>
	<brief_summary>The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.</brief_summary>
	<brief_title>A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>Chronic hepatitis C infection Unsuccessful prior HCV treatment Liver impairment (either AST or ALT 1.510.0 x ULN) Alphafetoprotein &lt;= 50 ng/mL Adequate hematologic parameters Decompensated or severe liver disease Hepatocellular carcinoma HIV infection Coinfection with hepatitis B virus (HBV) Renal impairment Pancreatitis Use of illicit or drugs of abuse History of alcohol abuse Presence of clinically significant cardiac arrhythmias If female, pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>